Vaccine developer Vaxcyte has floated in an upsized initial public offering having raised $110m in a Roche-backed round just three months ago.

Cullinan Oncology contributed to a series A round that funded the launch of a cancer drug-focused joint venture with PDI Therapeutics.

Muscle disease drug developer Avidity, which counts Eli Lilly, EMS, Takeda and ST Pharm as investors, went public in a significantly upized IPO.

Tencent-backed telemedicine service Miaoshou Doctor pulled in $84.5m that will support the strengthening of its health insurance provision.

Genomic heart disease drug developer Verve Therapeutics secured funding in a round led by GV, which also led its series A last year.

GenScript Biotech's spinoff Legend Biotech, which counts Eli Lilly and Johnson & Johnson as backers, floated in the US.

The emergency response software provider, which counts AAA, CSAA, Microsoft and Motorola Solutions as investors, lifted its total funding to $107m.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Remote care platform developer Conversa increased its total funding to more than $26m in a round co-led by Northwell Ventures and backed by UH Ventures.

AstraZeneca and Fresenius Medical Care will exit the kidney disease treatment developer in a $725m acquisition that could potentially rise to $2.1bn.